Imidazoline receptors: From discovery to antihypertensive therapy (facts and doubts)

Brain Research Bulletin

Volumn 49, Issue 5, 1999, Pages 317-331

  Farsang, C ^a   Kapocsi, J ^a  

^a Szent Imre Hospital   (Hungary)

Author keywords

Cardiovascular regulation; Clonidine; Imidazolines; Moxonidine; Receptors; Rilmenidine

Indexed keywords

14ALPHA HYDROXY 7,8 METHYLENEDIOXYALLOBERBANE; 2 (2 IMIDAZOLIN 2 YL)QUINOLINE; 2 (2 IMIDAZOLIN 2 YL)QUINOXALINE; 2 (2,3 DIHYDRO 2 BENZOFURANYL) 2 IMIDAZOLINE; 4 CHLORO 2 (2 IMIDAZOLIN 2 YLAMINO)ISOINDOLINE; ADRENALIN; ADRENERGIC RECEPTOR; AGMATINE; AGN 192403; ALPHA 2 ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; APRACLONIDINE; CIRAZOLINE; CLONIDINE; EFAROXAN; IDAZOXAN; IMIDAZOLINE DERIVATIVE; IMIDAZOLINE I1 RECEPTOR; IMIDAZOLINE I2 RECEPTOR; IMIDAZOLINE RECEPTOR; MOXONIDINE; MUSCARINIC RECEPTOR; OPIATE RECEPTOR; RECEPTOR SUBTYPE; RILMENIDINE; RS 45041 190; SEROTONIN 1A RECEPTOR; SEROTONIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOHIMBINE;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR AUTOREGULATION; DRUG RECEPTOR BINDING; HUMAN; HYPERTENSION; LIGAND BINDING; NERVE PROJECTION; NEUROMODULATION; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; HUMANS; LIGANDS; NEUROLOGY; RECEPTORS, DRUG; SIGNAL TRANSDUCTION;

EID: 0033565355     PISSN: 03619230     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-9230(99)00057-X     Document Type: Review

References (244)

1. Allan, D. R.; Penner, S. B.; Smyth, D. D. Renal imidazoline preferring sites and solute excretion in the rat. Br. J. Pharmacol. 108:870-875; 1993.
2. Allen, A. M.; Guyenet, P. G. Alpha-2-adrenoceptor-mediated inhibition of bulbospinal barosensitive cells of rat rostral medulla. Am. J. Physiol. 265:R1065-R1075; 1993.
3. Amaral, D. G.; Sinnamon, H. M. The locus ceruleus, neurobiology of a central noradrenergic nucleus. Prog. Neurobiol. 9:147-96; 1977.
4. Anderson, W. P.; Evans, R. G.; Malpas, S. C. Pressure natriuresis and long-term blood pressure control. J. Cardiovasc. Pharmacol. 26(suppl. 2):S17-S23; 1995.
5. Angel, I.; Le Rouzic, M.; Pimoule, C.; Graham, D.; Arbilla, S. (3H)-cirazoline as a tool for the characterization of imidazoline sites. Ann. N.Y. Acad. Sci. 763:112-124; 1995.
6. Armah, B. I.; Hofferber, E.; Stenzel, W. General pharmacology of the novel centrally acting antihypertensive agent moxonidine. Arzneimittel Forschung Drug Res. 38:1426-1434; 1988.
7. Atlas, D. Clonidine-displacing substance (CDS) and its putative imidazoline receptor. New leads for further divergence of α 2-adrenergic receptor activity. Biochem. Pharmacol. 41:1541-1549; 1991.
8. Atlas, D.; Burstein, Y. Isolation and partial purification of a clonidine-displacing endogenous brain substance. Eur. J. Biochem. 144:287-293; 1984.
9. Atlas, D.; Burstein, Y. Isolation of an endogenous clonidine-displacing substance from rat brain. FEBS Lett. 170:387-390; 1984.
10. Atlas, D.; Diamant, S.; Zonnenschein, R. Imidazoline receptors and the endogenous clonidine displacing substance (CDS). In: Szabadi, E.; Bradshaw, C. M., eds. Adrenoceptors: Structure, mechanisms, function. Basel: Birkhauser Verlag; 1991:91-100.
11. Barturen, F.; Meana, J. J.; Martin, I.; Garcia-Sevilla, J. A. Increased non-adrenoceptor (3H)idazoxan binding sites (NAIBS) in postmortem brains of suicide victims. Fundam. Clin. Pharmacol. 6(57s):27; 1992.
12. Beckett, P. J.; Finch, L. The α1-and α2-adrenoceptor involvement in the central cardiovascular action of clonidine in the conscious renal hypertensive cat. Eur. J. Pharmacol. 82:155-160; 1982.
13. Bohman, C.; Schollmeyer, P.; Rump, L. C. Effects of imidazolines on noradrenaline release in rat isolated kidney. Naunyn Schmiedebergs Arch. Pharmacol. 349:118-124; 1994.
14. Bousquet, P. Imidazoline receptors. Neurochem. Int. 30:3-7; 1997.
15. Bousquet, P. Imidazoline receptors: from basic concept to recent developments. J. Cardiovasc. Pharmacol. 26(suppl. 2):S1-S6; 1995.
16. Bousquet, P.; Feldman, J.; Atlas, D. An endogenous, non-catecholamine clonidine antagonist increases mean arterial blood pressure. Eur. J. Pharmacol. 124:167-170; 1986.
17. Bousquet, P.; Feldman, J.; Bloch, R.; Schwartz, J. The nucleus reticularis lateralis a region highly sensitive to clonidine. Eur. J. Pharmacol. 69:389-392; 1981.
18. Bousquet, P.; Feldman, J.; Schwartz, J. The medullary cardiovascular effects of imidazolines and some GABA analogues: A review. J. Auton. Nerv. 14:263-270; 1985.
19. Bousquet, P.; Feldman, J.; Tibirica, E.; Bricca, G.; Greney, H.; Dontenwill, M.; Stutzmann, J.; Belcourt, A. Imidazoline receptors. A new concept in central regulation of the arterial blood pressure. Am. J. Hypertens. 5:47S-50S; 1992.
20. Bousquet, P.; Feldman, J.; Schwartz, J. Central cardiovascular effects of adrenergic drugs: Difference between catecholamines and imidazolins. J. Pharmacol. Exp. Ther. 230:232-236; 1984.
21. Bousquet, P.; Greney, H.; Bennai, F.; Feldman, J.; Stutzman, J.; Belcourt, A.; Dontenwill, M. Imidazoline receptors and cardiovascular regulations: A statement. N.Y. Acad. Sci. 763:526-530; 1995.
22. Bousquet, P.; Guertzenstein, P. G. Localization of the central vascular action of clonidine. Br. J. Pharmacol. 49:573-579; 1973.
23. Bousquet, P.; Schwartz, J. Alpha-adrenergic drug: Pharmacological tools for the study off the central nervous system. Biochem. Pharmacol. 32:1459-1465; 1983.
24. Bricca, G.; Dontenwill, M.; Molines, A. Evidences for the existence of a homogenous population of imidazoline receptors in the human brainstem. Eur. J. Pharmacol. 150:401-402; 1988.
25. Bricca, G.; Dontenwill, M.; Molines, A.; Feldman, J.; Belcourt, A.; Bousquet, P. The imidazoline preferring receptor: Binding studies in bovine, rat and human brainstem. Eur. J. Pharmacol. 162:1-9; 1989.
26. Bricca, G.; Greney, H.; Dontenvill-Kieffer, M.; Zhang, J.; Belcourt, A.; Bousquet, P. Heterogeneity of specific imidazoline binding of (3H)idazoxan in the human cerebral cortex. Neurochem. Int. 22:153-163; 1993.
27. Bricca, G.; Greney, H.; Zhang, J.; Dontenwill, M.; Stutzmann, J.; Belcouer, A.; Bousquet, P. Human brain imidazoline receptors: Further characterization with (3H)clonidine. Eur. J. Pharmac-Molec. Pharmacol. Sect. 266:25-33; 1994.
28. Brown, C. A.; Loweth, A. C.; Smith, S. A.; Morgan, N. G. Stimulation of insulin secretion by imidazoline compounds is not due to interaction with non-adrenoceptor idazoxan binding sites. Br. J. Pharmacol. 108-117; 1993.
29. Brown, C. A.; Morgan, N. G. Control of insulin secretion by imidazolines in pancreatic islets. Biochem. Soc. Trans. 21:8109; 1993.
30. Bylund, D. B.; Ray-Prenger, C. Alpha-2A and α-2B adrenergic receptor subtypes: Attenuation of cyclic AMP production in cell lines containing only one receptor subtype. J. Pharmacol. Exp. Ther. 251:640-644;1989.
31. Bylund, D. B.; U Prichard, D. C. Characterization of α-1 and α-2 adrenergic receptors. Int. Rev. Neurobiol. 24:343-431; 1983.
32. Campbell, W. R.; Potter, D. E. Potential role of imidazoline (I1) receptors in modulating aqueous humor dynamics. J. Ocul. Pharmacol. 10:393-402; 1994.
33. Carpéné, C.; Collon, P.; Remaury, A.; Cordi, A.; Hudson, A.; Nutt, D.; Lafontan, M. Inhibition of amine oxidase activity by derivates recognizing I2-imidazoline sites. J. Pharmacol. Exp. Ther. 272:681-687; 1995.
34. Chalmers, J. P.; Pilowski, P. M. Brain stem and bulbospinal neurotransmitter systems in control of bloood pressure. J. Hypertens. 9:675-694; 1991.
35. Chan, C. K. S.; Head, G. A. Relative importance of central imidazoline receptors for the antihypertensive effects of moxonidine and rilmenidine. J. Hypertens. 14:855-864; 1996.
36. Chan, S. L.; Morgan, L. G. Stimulation of insulin secretion by efaroxan may involve interaction with potassium channels. Eur. J. Pharmacol. 176:97-101; 1990.
37. Chan, S. L. F.; Brown, C. A.; Morgan, N. G. Stimulation of insulin secretion by the imidazoline α-2 adrenoceptor antagonist efaroxan is mediated by a novel, stereoselective, binding site. Eur. J. Pharmacol. 230:375-378; 1993.
38. Chu, T. C.; Socci, R. R.; Ogidigben, M. J.; Potter, D. E. Potential mechanisms of moxonidine-induced ocular hypotension: role of norepinephrine. J. Ocul. Pharmacol. Ther. 13:489-496: 1997.
39. Convents, A.; Convents, D.; De Backer, J. P.; De Keyser, J.; Vauquelin, G. High afffinity binding of (3H)rauwolscin and (3H)RX781094 to α-2 adrenergic receptors and non stereoselective sites in human and rabbit brain cortex membranes. Biochem. Pharmacol. 38:445-463; 1989.
40. Conway, E. L.; Gundlach, A. L.; Craven J. A. Temporal changes in glial fibrillary acidic protein messenger RNA and (3H)PK11195 binding in relation to imidazoline-I2-receptor and α 2-adrenoceptor binding in the hippocampus following transient global forebrain ischemia in the rat. Neurocience 82:805-817; 1998.
41. Coupry, I.; Atlas, D.; Podevin, R. A.; Uzielli, I.; Parini, A. Imidazoline-guanidinum receptive site in renal proximal tubule: Asymetric distribution, regulation by cations and interaction with an endogenous clonidine displacing substance. J. Pharmacol. Exp. Ther. 252:293-299; 1990.
42. Coupry, I.; Podevin, R. A.; Dausse, J. P.; Parini, A. Evidence for imidazoline binding sites in basolateral membranes from rabbit kidney. Biochem. Biophys. Res. Comm. 147:1055-1060; 1987.
43. De Quattro, V.; Myura, Y. Neurogenic factors in hypertension: Mechanism or myth? Am. J. Med. 43:47-51; 1973.
44. De Sarro, G. B.; Ascioti, C.; Froio, F.; Libri, V.; Nistico, G. Evidence that locus ceruleus is the site where clonidine and drugs acting α-1 and α-2-adrenoceptors affect sleep and arousal mechanisms Br. J. Pharmacol. 90:675-685; 1987.
45. De Vos, H.; Bricca, G.; De Keyser, J.; De Backer, J. P.; Bousquet, P.; Vauquelin, G. Imidazoline receptors. Non-adrenergic idazoxan binding sites and α-2-adrenoceptors in the human central nervous system. Neuroscience 59:589-598; 1994.
46. Deckert, V.; Lachaud, V.; Parini, A.; Elghozi, J. L. Contribution of α-2 adrenoceptors to the central cardiovacular effects of clonidine and S8350 in anaesthetized rats. Clin. Exp. Pharmacol. Physiol. 18:401-408, 1991.
47. Diamant, S.; Atlas, D. An endogenous brain substance, CDS (clonidine displacing substance), inhibits the twitch response of rat vas deferens. Biochem. Biophys. Res. Commun. 134:184-190; 1986.
48. Diamant, S.; Eldar-Geva, T.; Atlas, D. Imidazole binding sites in human placenta: Evidence for heterogeneity and a search for physiological function. Br. J. Pharmacol. 106:101-108; 1992.
49. Diamant, S.; Eldor, A.; Atlas, D. A low molecular weight brain substance interacts, similarly to clonidine, with α-2 adrenoceptors of human platelets. Eur. J. Pharmacol. 144:247-255; 1987.
50. Dontenwill, M.; Bricca, G.; Molines, A.; Bousquet, P.; Belcourt, A. Production and characterization of anti-clonidine antibodies not cross-reacting with catecholamines. Eur. J. Pharmacol. 149:249-255; 1988.
51. Dontenwill, M.; Molines, A.; Bricca, G.; Stutzman, J.; Kempf, J. Production and characterization of an iminoimidazolidine specific monoclonal antibody using para-aminoclonidine as antigen. Life Sci. 50:1859-1868; 1992.
52. Dontenwill, M.; Molines, A.; Verdun, A.; Bricca, G.; Laurent, S.; Bousquet, P. A circulating substance cross-reacting with antiimidazoline antibodies. Detection in serum in relation to essential hypertension. J. Clin. Invest. 92:1068-1072; 1993.
53. Dubar, M.; Pillion, G. I1 agents: A new approach to the treatment of hypertension. Ann. N. Y. Acad. Sci. 763:642-658; 1995.
54. Dunne, M. J. Block of ATP-regulated potassium channels by phentolamine and other α-adrenoceptor antagonists. Br. J. Pharmacol. 103:1847-1850; 1991.
55. Ernsberger, P.; Collins, L. A.; Graves, M. F.; Dreshaj, I. A.; Haxhiu, M. A. Imidazoline I1 receptors in the ventrolateal medulla and their role in cardiorespiratory control. In Trouth, C. O.; Millis, R. M.; Kiwull-Schöne, H.; Schlafke, M. E., eds. Ventral brainstem mechanisms and control of respiration and blood pressure. New York/Basel/ Hong Kong: Marcel Dekker Inc.; 1995:319-358.
56. Ernsberger, P.; Damon, T. H.; Graff, L. M.; Schafer, S. G.; Christen, M. O. Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites. J. Pharmacol. Exp. Ther. 264:172-182; 1993.
57. Ernsberger, P.; Elliot, H. L.; Weimann, H. J.; Raap, A.; Haxhiu, M. A.; Hofferber, E.; Löw-Kröger, A.; Reid, J. L.; Mest, H. J. Moxonidine: A second-generation central antihypertensive agent. Cardiovasc. Drug Rev. 11:411-431; 1993.
58. Ernsberger, P.; Friedman, J. E.; Koletsky, J. The I1 imidazoline receptor: from binding site to therapeutic target in cardiovascular disease. J. Hypertens. 15(suppl. 1):S9-S23; 1997.
59. Ernsberger, P.; Giuliano, R.; Willette, R. N.; Reis, D. J. Role of imidazole receptors in the vascular response to clonidine analogs in the rostral ventrolateral medulla. J. Pharmacol. Exp. Ther. 253:408-418; 1990.
60. Ernsberger, P.; Graves, M. E.; Graff, L. M.; Zakieh, N.; Nguyen, P. I1 imidazoline receptors. Definition, Characterization, distribution and transmembrane signaling. Ann. N.Y. Acad. Sci. 763:22-42; 1995.
61. Ernsberger, P.; Haxhiu, M. A. The I1-imidazoline-binding site is a functional receptor mediating vasodepression via ventral medulla. Am. J. Physiol. 273(5 Pt2):R1572-R1579; 1997.
62. Ernsberger, P.; Koletsky, R. J.; Collins, L. A.; Bedol, D. Sympathetic nervous system in salt-sensitive and obese hypertension: Amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc. Drugs Ther. 10:275-282; 1996.
63. Ernsberger, P.; Meely, M. P.; Mann, J. J.; Reis, D. J. Clonidine binds to imidazole binding sites as well as α-2 adrenoceptors in ventrolateral medulla. Eur. J. Pharmacol. 134:1-13; 1987.
64. Ernsberger, P.; Meely, M. P.; Reis, D. J. An endogenous substance with clonidine-like properties: Selective binding to imidazole sites in the ventrolateral medulla. Brain Res. 441:309-318; 1988.
65. Ernsberger, P.; Meely, M. P.; Reis, D. J. Neuroblastomaglioma hybrid cells contain clonidine displacing substance. Eur. J. Pharmacol. 174:135-138; 1989.
66. Ernsberger, P.; Shen, I. H. Plasma membrane localization and guanin nucleotid sensitivity of medullary I1-imidazoline binding sites. Neurochem. Int. 30(1):17-23; 1997.
67. Escriba, P. V.; Sastre, M.; Wang, H.; Regunathan, S.; Reis, D. J.; Garcia-Sevilla, J. A. Immunodetection of putative imidazoline receptor proteins in the human and rat brain and other tissues. Neurosci. Lett. 178:81-84; 1994.
68. Evans, R. G.; Haynes, J. M. Characterisation of binding sites for (3H)-idazoxan, (3H)-p-aminoclonidine and (3H)-rauwolscine in the kidney of the dog. Clin. Exp. Pharm. Phys. 21:649-658; 1994.
69. Evinger, M. J.; Ernsberger, P.; Regunathan, S.; Reis, D. J. Regulation of phentolamine N-methyltransferase gene expression by imidazoline receptors in adrenal chromaffin cells. J. Neurochem. 65:988-997; 1995.
70. Exton, J. H. Phosphatidylcholine breakdown and signal transduction. Biochym. Biophys. Acta. 1212:26-42; 1994.
71. Farsang, C.; Kapocsi, J.; Vajda, L.; Varga, K.; Malisák, Z.; Fekete, M.; Kunos, G. Reversal by naloxone of antihypertensive action of clonidine: Involvement of the sympathetic nervous system. Circulation 69:461-467; 1984.
72. Fatima, B.; Hugues, G.; Giampiero, B.; Alain, B.; Pascal, B.; Dontenwill, M. Polyclonal antiidazoxan antibodies: Characterization and purification. Fur. J. Pharmacol. 246:45-51; 1993.
73. Feldman, J.; Tibirica, F.; Bricca, G.; Dontenwill, M.; Belcourt, A.; Bousquet, P. Evidence for the involvement of imidazoline receptors in the hypotensive effect of rilmenidine in the rabbit. Br. J. Pharmacol. 100:600-604; 1990.
74. Felsen, D.; Ernsberger, P.; Meely, M. P.; Reis, D. J. Clonidine displacing substance is biologically active on smooth muscle. Fur. J. Pharmacol. 142:453-455; 1987.
75. Felsen, D.; Ernsberger, P.; Sutaria, P. M.; Nejat, R. J.; Nguyen, P.; May, M.; Breslin, D. S.; Marion, D. N.; Vughan, E. D., Jr. Identification, localization and functional analysis of imidazoline and α adrenergic receptors in canine prostate. J. Pharm. Exp. Ther. 268: 1063-1071; 1994.
76. Flamez, A.; De Backer, J. P.; Czerwiec, F.; Ladure, P.; Vauquelin, G. Pharmacological characterization of 11 and 12 imidazoline receptors in human striatum. Neurochem. Int. 30(1):25-29; 1997.
77. Fuder, H.; Schwartz, P. Desensitization of inhibitory prejunctional α-2 adrenoceptors and putative imidazoline receptors on rabbit heart sympathetic nerves. Naunyn Schmiedebergs Arch. Pharmacol. 348: 127-133; 1993.
78. Fuder, H.; Selbach, M. Characterization of sensory neurotransmission and its inhibition via α-2B adrenoceptors and via non-α-2 adrenoceptors in rabbit iris. Naunyn Schmiedebergs Arch. Pharmacol. 347: 394-401; 1993.
79. 78a. Gaiser, E. G.; Trendelenburg, A. U.; Starke, K. A search for presynaptic imidazoline receptors at rabbit and rat noradrenergic neurones in the absence of α2-autoinhibition. Naunyn Schmiedebergs Arch. Pharmacol. 359:123-132; 1999.
80. Garcia-Sevilla, J. A.; Escriba, P. V.; Walzer, C.; Bouras, C.; Guimon, J. Imidazoline receptor proteins in brains of patients with Alzheimer's disease. Neurosci. Lett. 247(2/3):95-98; 1998.
81. Gargalidis-Moudanos, C.; Pizzinat, N.; Javoy-Agid, F.; Remaury, A.; Parini, A. I2-imidazoline binding sites and monoamine oxidase activity in human postmortem brain from patients with Parkinson disease. Neurochem. Int. 30(1):31-36; 1997.
82. Glavin, G. B.; Carlisle, M. A.; Smyth, D. D. Agmatine, an endogenous imidazoline receptor agonist, increase gastric secretion and worsens experimental gastric mucosal injury in rats. J. Pharmacol. Exp. Ther. 274:741-744; 1995.
83. Goldberg-Stern, H.; Atlas, D.; Schwartz, L.; Achiron, A.; Ziv, I. Detection and measurement of an endogenous clonidine-displacing substance in human cerebrospinal fluid. Brain Res. 601:325-328; 1993.
84. Gomez, R.; Ernsberger, P.; Feinland, G.; Reis, D. J. Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area. Fur. J. Pharmacol. 195:181-191; 1991.
85. Gomez, R. F.; Ernsberger, P.; Feinland, G.; Reis, D. J. Rilmenidine lowers arterial pressure via imidazole receptors in brainstem C1 area. Fur. J. Pharmacol. 195:181-191; 1991.
86. Göthert, M.; Molderings, G. J. Involvement of presynaptic imidazoline receptors in the α-2 adrenoceptor-independent inhibition of noradrenaline release by imidazoline derivates. Naunyn Schmiedebergs Arch. Pharmacol. 343:271-282; 1991.
87. Göthert, M.; Molderings, G. J.; Fink, K.; Schlicker, E. Alpha-adrenoceptor-independent inhibition by imidazolines and guanidines of noradrenaline release from peripheral, but not central noradrenergic neurones. Ann. N. Y. Acad. Sci. 763:405-419; 1995.
88. Göthert, M.; Schlicker, F.; Heintrich, F.; Rohm, Z.; Zerkowski, H. R. Modulation of noradrenaline release in human saphenous vein via presynaptic α-2 adrenoceptors. Eur. J. Pharmacol. 102:261-271; 1984.
89. Greney, H.; Bennai, F.; Molines, A.; Belcourt, A.; Dontenwill, M.; Bousquet, P. Isolation of a human cerebral imidazoline specific binding protein. Eur. J. Pharmacol. 265:R1-2; 1994.
90. Greney, H.; Bricca, G.; Dontenwill, M.; Stutzmann, J.; Bousquet, P.; Belcourt, A. Characterization of imidazoline binding protein(s) sol-ubilized from human brainstem: Studies with (3H)idazoxan and (3H)clonidine. Neurochem. Int. 25:183-191; 1994.
91. Gustafson, I.; Westerberg, E.; Wieloch, T. Protection against ischemia-induced neuronal damage by the α 2-adrenoceptor antagonist idazoxan: Influence of time of administration and possible mechanisms of action. J. Cereb. Blood Flow Metab. 10:885-894; 1990.
92. Guyenet, P. G.; Lynch, K. R.; Allen, A. M.; Rosin, D. L.; Stornetta, R. L. Alpha-2-adrenergic receptors rather than "imidazoline" binding sites mediate the sympatholytic effect of clonidine in the rostral ventrolateral medulla: A new look at the evidence. In: Trouth, C. O.; Millis, R. M.; Kiwull-Schöne, H.; Schlafke, M. E., eds. Ventral brainstem mechanisms and control functions. New York: Marcel Dekker Inc.; 1993:319-358.
93. Hamilton, C. A.; Yakubu, M.; Jardine, E.; Reid, J .L. Imidazole binding sites in rabbit kidney and forebrain membranes. J. Auton. Pharmacol. 11:277-283; 1991.
94. Hársing, L. G., Jr.; Kapocsi, J.; Vizi, E. S. Possible role of α-2 and α-1 adrenoceptors in the experimentally induced depression of central nervous system. Pharmacol. Biochem. Behav. 32:927-932; 1989.
95. Head, G. A.; Chan, C. K. S.; Godwin, S. J. Central cardiovascular action of agmatine, a putative clonidin-displacing substance, in conscious rabbit. Neurochem. Int. 30(1):37-45; 1997.
96. Head, G. A.; Gundlach, A. L.; Musgrave, I. F. Recent advances in imidazoline receptor research: Ligands-localization and isolationsignaling-functional and clinical studies. J. Auton. Nerv. Syst. 72: 74-79; 1998.
97. Hieble, J. P.; Kolpak, D. C. Mediation of the hypotensive action systematic clonidine in the rat by α-2-adrenoceptors. Br. J. Pharmacol. 110:1635-1639; 1993.
98. Hohage, H.; Hess, K.; Jahl, C.; Greven, J.; Schlatter, E. Renal and blood pressure effects of moxonidine and clonidine in spontaneously hypertensive rats. Clin. Nephrol. 48(6):346-352; 1997.
99. Hudson, A. L.; Chapleo, C. B.; Lewis, J. W.; Husbands, S.; Grivas, K.; Mallard, N. J.; Nutt, D. J. Identification of ligands selective for central I2-imidazoline binding sites. Neurochem. Int. 30(1):47-53; 1997.
100. Hudson, A. L.; Mallard, N.; Nutt, D.; Chapleo, C. Affinity and selectivity of 2-(2-benzofuranyl)-2-imidazoline for mammalian brain non-adrenoceptor idazoxan binding sites (I1-sites). Br. J. Pharmacol. 114:411P; 1995.
101. Hussain, J. F.; Miall, F.; Patil, P.; Miller, D.; Kendall, D. A.; Wilson, V. G. Isothiocyanate tolazoline interacts with non-adrenoceptor, imidazoline binding sites labelled by (3H)-idazoxan. Fundam. Clin. Pharmacol. 6(1):P13; 1992.
102. Ivanov, T. R.; Feng, Y.; Wang, H.; Regunathan, S.; Reis, D. J.; Chikkala, D. N.; Gupta, P.; Jones, J. C.; Piletz, J. E. Imidazoline receptor proteins are regulated in platelet-precursor MEG-01 cells by agonists and antagonists. J. Psychiatr. Res. 32(2):65-79; 1998.
103. Ivanov, T. R.; Zhu, H.; Regunathan, S.; Reis, D. J.; Dontenwill, M.; Vonthron, C.; Bousquet, P.; Piletz, S. E. Codetection by two imidazoline receptor protein antisera of a novel 84 kilodalton protein. Biochem. Pharmacol. 55(5):649-55; 1998.
104. Ivkovic, B.; Bakthavachalam, V.; Neumeyer, J.; Lanier, S.; Brasili, L.; Pigini, M. Cirazoline derivates as molecular probes for imidazoline-guanidinium receptive site (IGRS). Fundam. Clin. Pharmacol. 6(I/II):11; 1992.
105. Ivkovic, B.; Bakthavachalam, V.; Zhang, W.; Parini, A.; Diz, D.; Bosch, S.; Singh, I.; Neumeyer, J. L.; Lanier, S. M. Development of a high-affinity radionated ligand for identification of imidazoline/ guanidine receptive sites (IGRS): Intratissue distribution of IGRS in liver, forebrain and kidney. J. Pharmacol. Exp. Ther. 46:15-23; 1994.
106. Jackson H. C.; Nutt, D. J. Are 5-HT receptors or β-adrenoceptors involved in idazoxan-induced food and water intake? Neuropharmacology 31:1081-1087; 1992.
107. Jackson, H. C.; Griffin, I. J.; Nutt, D. J. The effects of idazoxan and other α 2-adrenoceptor antagonists on food and water intake in the rat. Br. J. Pharmacol. 104:258-262; 1991.
108. Julius, S. The evidence for a pathophysiologic significance of the sympathetic overactivity in hypertension. Clin. Exp. Hypertens. 18: 305-321; 1996.
109. Kaan, E. C.; Brückner, R.; Frohly, P.; Tulp, M.; Scharer, S. G.; Ziegler, D. Effects of agmatine and moxonidine on glucose metabolism. Cardiovasc. Risk. Fact. 5(suppl. 1):19-27; 1995.
110. Kalra, S. P.; Pearson, E.; Sahu, A.; Kalra, P. S. Agmatine, a novel hypothalamic amine, stimulates pituitary luteinizing hormone release in vivo and hypothalamic luteinizing hormone-releasing hormone release in vitro. Neurosci. Lett. 194:165-168; 1995.
111. Kamisaki, I.; Ishikawa. T.; Takao, T.; Omodani, H.; Kuno, N.; Itoh, I. Binding of (3H)p-aminoclonidine to two sites, α-2 adrenoceptors and imidazoline binding sites: Distribution of imidazoline binding sites in rat brain. Brain Res. 514:15-21; 1990.
112. Kapocsi, J.; Zimányi, I.; Farsang, C.; Vizi, E. S. Presynaptic α-2 adrenoceptors exclusively sensitive to agonists of phenylethylamine structure on the sympathetic nerves of the human gall bladder artery. Neurosci. Res. 4:413-418; 1987.
113. Karppanen, H. Interrelationship between clonidine and histaminergic mechanisms. Trends Pharmacol. Sci. 2:35-37; 1981.
114. Karppanen, H.; Paakkari, I.; Paakkari, P.; Huotari, R.; Orma, A. L. Possible involvement of central histamine H2-receptors in the hypotensive effect of clonidine. Nature 259:587-588; 1976.
115. King, P. R.; Gundlach, A. L.; Jarrott, B.; Louis, W. J. Nature of (3H)rilmenidine binding to membranes of rat cerebral cortex. Am. J. Hypertens. 5:S64-S68; 1992.
116. Kline, R. L.; Mark, J.; Cechetto, D. F. Natriuretic effect of rilmenidine in anesthetised rats. Am. J. Cardiol. 74:20A-24A; 1994.
117. Kobinger, W. Central adrenergic system s targets for antihypertensive drugs. Rev. Physiol. Biochem. Pharmacol. 81:40-63; 1978.
118. Kou, Y. R.; Ernsberger, P.; Cragg, P. A. Role of α-2 adrenergic receptors in the carotid body response to isocapnic hypoxia. Respir. Physiol. 83:535-364; 1991.
119. Kreisberg, G. A.; Diamant, S.; Diamant, Y. Z.; Atlas, D. Raised levels of an endogenous nonadrenergic substance in the serum of pregnancy-induced hypertension patients. Isr. J. Med. Sci. 23:1194-1197; 1987.
120. Kunos, G.; Farsang, C.; Ramirez-Gonzales, M. D. Beta-endorfin: Possible involvement in the antihypertensive effect of central α-receptor activation. Science 211:82-86; 1981.
121. Lachaud, V.; Coupry, I.; Podevin, R. A.; Dausse, J. P.; Koenig, E.; Parini, A. Interaction of clonidine and rilmenidine with imidazolinepreferring receptors. J. Hypertens. 6(suppl. 4):S511-S513; 1988.
122. Lachaud-Pettiti, V.; Podevin, R. A.; Chretien, I.; Parini, A. Imidazoline-guanidinium receptive sites in basolateral membranes from human kidney. Eur. J. Pharmacol. 206:23-31; 1991.
123. Lacombe, C.; Viallard, V.; Paris, H. Identification of α-2 adrenoceptors and of non-adrenergic idazoxan binding sites in pancreatic islets from young and adult hamsters. Int. J. Biochem. 25:1077-1083; 1993.
124. Lalies, M. D.; Nutt, D. J. A microdilysis study of the neurochemical effects in rat striatum of RX821029, a selective ligand for non-adrenoceptor binding sites. Br. J. Pharmacol. 109:85P; 1993.
125. Langin, D.; Lafontan, M. (3H)idazoxan binding at non-α 2 adrenoceptors in rabbit adipocyte membranes. Eur. J. Pharmacol. 159:199-203; 1989.
126. Lanier, S. M.; Ivkovic, B.; Singh, I.; Neumeyer, J. L.; Bakthavachalam, V. Visualization of multiple imidazoline/guanidinum-receptive sites. J. Biol. Chem. 268:16047-16051; 1993.
127. Laragh, J. H. Rilmenidine and the high risk hypertensive patient. Ann. N. Y. Acad. Sci. 763:634-641; 1995.
128. Li, G.; Regunathan, S.; Barrow, C. J.; Eshraghi, J.; Cooper, R.; Reis, D. J. Agmatine: An endogenous clonidine-displacing substance in the brain. Science 263:966-969; 1994.
129. Liedtke, C. M.; Ernsberger, P. Regulation of elektrolyte transport in rabbit tracheal epithelial cells by the I1-imidazoline agonist moxonidine. Ann. N. Y. Acad. Sci. 763:401-404; 1995.
130. Liedtke, C. M.; Furin, J.; Ernsberger, P. Alpha-2 adrenergic, but not imidazole, agonists activate NaC1 cotransport in rabbit tracheal epithelial cells. Am. J. Physiol. Cell. Physiol. 264:C568-C576; 1993.
131. Loring, R. H. Agmatine acts as an antagonist of neuronal nicotinic receptors. Br. J. Pharmacol. 99:207-211; 1990.
132. MacKinnon, A. C.; Brown, C. M.; Spedding, M.; Kilpatrick, A. T. (3H)-Idazoxan binds with high affinity to two sites on hamster adipopcytes: An α-2 adrenoceptor and a non-adrenoceptor site. Br. J. Pharmacol. 98:2243-1150; 1989.
133. MacKinnon, A. C.; Redfern, W. S.; Brown, C. M. (3H)-RS-45041-190, a selective high affinity radioligand for I2-imidazoline receptors. Br. J. Pharmacol. 106:1019-1027; 1995.
134. MacKinnon, A. C.; Stewart, M.; Olverman, H. J.; Spedding, M.; Brown, G. M. (3H)p-aminoclonidine and (3H)idazoxan label different population of imidazoline sites in rat kidney. Eur. J. Pharmacol. 232:79-87; 1993.
135. MacMillan, L. B.; Hein, L.; Smith, M. S.; Piascik, M. T.; Limbird, L. E. Central hypotensive effects of α-2a-adrenergic receptors subtype. Science 273:801-803; 1996.
136. Maiese, K.; Pek, L.; Berger, S. B.; Reis, D. J. Reduction in focal cerebral ischemia by agents acting at imidazole receptors. J. Cereb. Blood Flow Metab. 12:53-63; 1992.
137. Mallard, N. J.; Hudson, A. L.; Nutt, D. J. Characterization and autoradiographical localization of non-adrenoceptor idazoxan binding sites in the rat brain. Br. J. Pharmacol. 106:1019-1027; 1992.
138. McCrimmon, D. R.; Lalley, P. M. Inhibition of respiratory neural discharges byclonidine and 5-hydroxytryptophan. J. Pharmacol. Exp. Ther. 222:771-777; 1982.
139. Meana, J. J.; Barturen, F.; Martin, L.; Garcia-Sevilla, J. A. Evidence of increased nonadrenoceptor (3H)idazoxan binding sites in the frontal cortex of depressed suicide victims. Biol. Psychiatry 34:498-501; 1993.
140. Meely, M. P.; Ernsberger, P. R.; Granata, A. R.; Reid, D. J. An endogenous clonidine-displacing substance from bovine brain: Receptor binding and hypotensive actions in ventrolateral medulla. Life Sci. 38:1119-1126; 1986.
141. Meely, M. P.; Hensley, M. L.; Ernsberger, P.; Felsen, D.; Reis, D. J. Evidence for a bioactive clonidine-displacing substance in peripheral tissue and serum. Biochem. Pharmacol. 44:733-740; 1992.
142. Michel, M. C.; Brodde, O. E.; Schnepel, B.; Behrendt, J.; Tschada, R. (3H)idazoxan and some other α-2 adrenergic drugs also bind with high affinity to a nonadrenergic site. Mol. Pharmacol. 35:324-330; 1989.
143. Michel, M. C.; Ernsberger, P. Keep an eye on the I site: Imidazoline preferring receptors. Trends Pharmacol. Sci. 13:369-370; 1992.
144. Michel, M. C.; Insel, P. A. Are there multiple imidazoline binding sites? Trends Pharmacol. Sci. 10:342-344; 1989.
145. Michel, M. C.; Regan, J. W.; Gerhardt, M. A.; Neubig, R. R.; Insel, P. A.; Motulsky, H. J. Nonadrenergic (3H)idazoxan binding sites are physically distinct from α-2 adrenergic receptors. Mol. Pharmacol. 37:65-68; 1990.
146. Miralles, A.; Olmos, G.; Sastre, M.; Barturen, F.; Martin, I.; Garcia-Sevilla, J. A. Discrimination and pharmacological characterization of I2-imidazoline sites with (3H)idazoxan and α-2 adrenoceptors with (3H)RX821002 (2-methoxy idazoxan) in the human and rat brains. J. Pharm. Exp. Ther. 264:1187-1197; 1992.
147. Molderings, G. J.; Göthert, M. Inhibitory presynaptic imidazoline receptors on sympathetic nerves in the rabbit aorta differ from I1-and I2-imidazoline binding sites. Naunyn Schmiedebergs Arch. Pharmacol. 351:507-516; 1995.
148. Molderings, G. J.; Heintrich, F.; Göthert, M. Pharmacological characterization of the imidazoline receptor which mediates inhibition of noradrenaline release in the rabbit pulmonary artery. Naunyn Schmiedebergs Arch. Pharmacol. 344:630-638; 1991.
149. Molderings, G. J.; Kundt, L.; Göthert, M. (3H)idazoxan binding to bovine adrenal medullary membranes: Identification and pharmacological characterization of I2-imidazoline sites. Naunyn Schmiedebergs Arch. Pharmacol. 350:252-257; 1994.
150. Molderings, G. J.; Likungu, J.; Jakszklik, J.; Göthert, M. Presynaptic imidazoline receptor and non-adrenoceptor (3H)-idazoxan binding sites in human cardiovascular tissues. Br. J. Pharmacol. 122(1):43-50; 1997.
151. Molderings, G. J.; Moura, D.; Fink, K. Binding of (3H)clonidine to I1-imidazoline sites in bovine adrenal medullary membranes. Naunyn Schmiedebergs Arch. Pharmacol. 348:70-76; 1993.
152. Mosqueda-Garcia, R. Guanfacine: A second generation α-2 adrenergic blocker. Am. J. Med. Sci. 299:73-76; 1990.
153. 151a. Munk, S. A.; Lai, R. K.; Burke, J. E.; Arasasingham, P. N.; Kharlamb, A. B.; Manlapaz, C. A.; Padillo, E. U.; Wijono, M. K.; Hasson, D. W.; Wheeler, L. A.; Garst, M. E. Synthesis and pharmacologie evaluation of 2-endo-amino-3-exo-isopropylbicyclo[2.2.1]heptane: A potent imidazolinel receptor specific agent. J Med. Chem. 39(6): 1193-1195; 1996.
154. Nutt, D. J.; French, N.; Handley, S.; Hudson, A.; Husbannds, S.; Jackson, H.; Jordan, S.; Lalies, M. D.; Lewis, J.; Lione, L.; Mallard, N.; Pratt, J. Functional studies of specific imidazoline-2 receptors ligands. Ann. N. Y. Acad Sci. 763:125-139; 1995.
155. Okumara, K.; Ichiara, K.; Nagasaka, M. Effects of imidazolinerelated compounds on mechanical response to nicorandil in the rat portal vein. Eur. J. Pharmacol. 215:253-257; 1992.
156. Olmos, G.; Alemany, R.; Escriba, P. V.; Garcia-Sevilla, J. A. The effects of chronic imidazoline drug treatment on glial fibrillary acidic protein concentration in rat brain. Br. J. Pharmacol. 111:997-1002; 1994.
157. Parini, A.; Coupry, I.; Graham, R. M.; Uzielli, I.; Atlas, D.; Lanier, S. M. Characterization of an imidazoline/guanidinum receptive site distinct from the α 2 adrenergic receptor. J. Biol. Chem. 264:11874-11878; 1989.
158. Parini, A.; Moudanos, C. G.; Pizzinat, N.; Lanier, S. M. The elusive family of imidazoline binding sites. Trends Pharmacol. Sci. 17:13-16; 1996.
159. Penner, S. B.; Smyth, D. D. Renal denervation altered hemodynamic and adrenal effects following intracerebroventricular administration of the I1-imidazoline receptor agonist, rilmenidine, in pentobarbital anaesthetised rats. Neurochem. Int. 30(1):55-62; 1997.
160. Penner, S. B.; Smyth, D. Sodium excretion following central administration of an I1 imidazoline receptor agonist, moxonidin. Br. J. Pharmacol. 112:1089-1094; 1994.
161. Penner, S. B.; Smyth, D. The role of the peripheral sympathetic nervous system in the natruresis following central administration of an I1-imidazoline agonist, moxonidine. Br. J. Pharmacol. 116:2631-2636; 1995.
162. Pigini, M.; Bousquet, P.; Carotti, A.; Dontenwill, M.; Gianella, M.; Moriconi, R.; Piergentili, A.; Quaglia, W.; Tayebati, S. K.; Brasili, L. Imidazoline receptors: Qualitative structure-activity relationships and discovery of tracizoline and benazoline. Two ligands with high affinity and unprecedented selectivity. Bioorg. Med. Chem. 5(5): 833-841; 1997.
163. Piletz, J. F.; Andorn, A. C.; Unnerstall, J. R.; Halaris, A. Binding of (3H)-p-aminoclonidine to α-2 adrenoceptor states plus a non-adrenergic site on human platelet plasma membranes. Biochem. Pharmacol. 42:569-584; 1991.
164. Piletz, J. F.; Sletten, K. Nonadrenergic imidazoline binding sites on human platelets. J. Pharmacol. Exp. Ther. 267:1493-1502; 1993.
165. Pinthong, D.; Wright, I. K.; Hanmer, C.; Millns, P.; Mason, R. Agmatine recognizes α-2 adrenoceptor binding sites but neither activates nor inhibits α-2 adrenoceptors. Naunyn Schmiedebergs Arch. Pharmacol. 351:10-16; 1995.
166. Powis, D. A.; Baker, P. F. Alpha-2 adrenergic receptors do not regulate catecholamine secretion by bovine adrenal medullary cells: Study with clonidine. Mol. Pharmacol. 29:134-141; 1986.
167. Raddatz, R.; Lanier, S. M. Relationship between imidazoline/guanidinum receptive sites and monoamine oxidase A and B. Neurochem. Int. 30(1):109-117; 1997.
168. Reaven, G. M. Role of insulin resistance in human disease (syndrome X): An expanded definition. Ann. Rev. Med. 44:121-131; 1993.
169. Reaven, G. M.; Lithell, H.; Landsberg, L. Hypertension and associated metabolic abnormalities - the role of insulin resistence and the sympathoadrenal system. N. Engl. J. Med. 334:374-381; 1996.
170. Regunathan, S.; Evinger, M. J.; Meely, M. P.; Reis, D. J. Effects of clonidine and other imidazoline-receptors binding agents on second messenger systems and calcium influx in bovine adrenal chromaffin cells. Biochem. Pharmacol. 42:2011-2018; 1991.
171. Regunathan, S.; Feinstein, D. L.; Raasch, W.; Reids, D. J. Agmatine, the decarboxylated arginine, is localized and syntetized in glial cells. Neuroreport 6:1897-1900; 1995.
172. Regunathan, S.; Feinstein, D. L.; Reis, D. J. Expression of non-adrenergic imidazoline sites in rat cerebral cortical astrocytes. J. Neurosci. Res. 34:681-688; 1993.
173. Regunathan, S.; Meely, M. P.; Reis, D. J. Clonidine-displacing substance from bovine brain binds to imidazoline receptors and releases catecholamines in adrenal chromaffin cells. Mol. Pharmacol. 40:884-888; 1991.
174. Regunathan, S.; Meely, M. P.; Reis, D. J. Effect of clonidine on second messenger system in rat adrenal gland. Life Sci. 47:2127-2133; 1990.
175. Regunathan, S.; Meely, M. P.; Reis, D. J. Expression of non-adrenergic imidazoline sites in chromaffin cells and mitochondrial membranes of bovine adrenal. Biochem. Pharmacol. 45:1667-1675; 1993.
176. Regunathan, S.; Reis, D. J. Effects of moxonidine, an imidazoline antihypertensive agent, on second messenger system in rat brain. Eur. J. Pharmacol. 269:273-276; 1994.
177. Regunathan, S.; Reis, D. J. Imidazoline receptors and their endogenous ligands. Ann. Rev. Pharmacol. Toxicol. 36:511-544; 1996.
178. Regunathan, S.; Youngson, C.; Raasch, W.; Wang, H.; Reis, D. J. Imidazoline receptors and agmatine in blood vessel: A novel system inhibiting vascular smooth muscle proliferation. J. Pharm. Exp. Ther. 276(3): 1272-1282; 1996.
179. Reis, D. J. Neurones and receptors in the rostral ventrolateral medulla mediating the antihypertensive actions of "imidazoline" drugs. J. Cardiovasc. Pharmacol. 27(suppl. 3):S11-S18; 1996.
180. Reis, D. J.; Golanov, E. V.; Ruggerio, D. A.; Sun, M. K. Sympathoexcitatory neurons of the rostral medulla are oxygensensors and essential elements in the tonic and reflex control of the systemic and cerebral circulations. J. Hypertens. 12(suppl. 1):59-80; 1994.
181. Reis, D. J.; Regunathan, S. Agmantine: A novel neurotransmitter? Eur. J. Pharmacol. 331:133-138; 1998.
182. Romanovsky, A. A.; Shido, O.; Ungar, A. L.; Blatteis, C. M. Genesis of biphasic thermal response to intrapreoptically microinjected clonidine. Brain Res. Bull. 31:509-513; 1993.
183. Ruffolo, R. R.; Turowski, B. S.; Patil, P. N. Lack of cross-desensitization between structurally dissimilar α-adrenoceptor agonists. J. Pharm. Pharmacol. 29:378-380; 1977.
184. Ruggerio, D. A.; Regunathan, S.; Wang, H.; Milner, T. A.; Reis, D. J. Distribution of imidazoline receptor binding protein in the central nervous system. Ann. N. Y. Acad. Sci. 763:208-221; 1995.
185. Ruiz, J.; Martin, I.; Callado, L. F.; Meana, J. J.; Barturen, F.; Garcia-Sevilla, J. A. Non-adrenoceptor (3H)idazoxan binding sites (I2-imidazoline sites) are increased in postmortem brain from patients with Alzheimer's disease. Neurosci. Lett. 160:109-112; 1993.
186. Safar, M. E. Rilmenidine: A novel antihypertensive agent. Am. J. Med. 87(suppl. 3C):24S-29S; 1989.
187. Sakuta, H.; Okamoto, K. Inhibition by imidazoline and imidazoline derivatives of glibenclamide-sensitive K+ currents in Xenophus oocytes. Eur. J. Pharmacol. 259:223-231; 1994.
188. Sastre, M.; Garcia-Sevilla, J. A. Densities of I2-imidazoline receptors, α-2 adrenoceptors and monoamine oxidase B in brains of suicide victims. Neurochem. Int. 30(1):63-72; 1997.
189. Sastre, M.; Garcia-Sevilla, J. A. Opposite age-dependent changes of α-2 adrenoceptors and non-adrenerg (3H)idazoxan binding sites (I2-imidazoline sites) in the human brain: Strong correlation of 12 with monoamine oxidase-B sites. J. Neurochem. 61:881-889; 1993.
190. Schlicker, E.; Armah, B. I.; Göthert, M. Central presynaptic α-2 autoreceptors are involved in the blood presure-lowering effects of moxonidine. J. Cardiovasc. Pharmacol. 16:15-22; 1990.
191. Schlicker, E.; Fink, K.; Kathmann, M.; Molderings, G. J.; Göthert, M. Effects of imidazolines on noradrenaline release in brain: an investigation into their relationship to imidazoline, α-2 and H3 receptors. Neurochem. Int. 30(1):73-83; 1997.
192. Schmitt, H. The pharmacology of clonidine and related products. In: Gross, F., ed. Antihypertensive agents. Berlin: Springer-Verlag; 1977:301-341.
193. Schultz, A.; Hasselblatt, A. An insulin-releasing property of imidazoline derivates is not limited to compounds that block adrenoceptors. Naunyn Schmiedebergs Arch. Pharmacol. 340:321-327; 1989.
194. Senard, J.; Langin, M.; Estaan, L.; Paris, H. Identification of α-2 adrenoceptors and non-adrenergic idazoxan binding sites in rabbit colon epithelial cells. Eur. J. Pharmacol. 191:59-68; 1990.
195. Sener, A.; Lebrun, P.; Blachier, F.; Malaisse, W. J. Stimulus-secretion coupling of arginine-induced insuline release: Insulinotropic action of agmatine. Biochem. Pharmacol. 38:327-330; 1989.
196. Separovic, D.; Kester, M.; Ernsberger, P. Coupling of I1-imidazoline receptors to diacylglyceride accumulation in PC12 rat pheochromocytoma cells. Mol. Pharmacol. 49:668-675; 1996.
197. Separovic, D.; Kester, M.; Haxhiu, M. A.; Ernsberger, P. Activation of phosphatidylcholin-selective phospholipase C by I1-imidazoline receptors in PC12 cells and rostral ventrolateral medulla. Brain Res. 749:335-339; 1997.
198. Sjoholm, B.; Savola, J. M.; Scheinin, M. Noradrenergic binding of (3H)atipamezole in rat lung. A novel imidazole binding site? Ann. N. Y. Acad. Sci. 763:66-77; 1995.
199. Smyth, D. D.; Penner, S. B. Renal I1-imidazoline receptor-selective compounds mediate natruresis in the rat. J. Cardiovasc. Pharmacol. 26(suppl. 2):S63-S67; 1995.
200. Stornetta, R. L.; Huangfu, D.; Rosin, D. L.; Lynch, K. R.; Guyenet, P. G. Alpha-2 adrenergic receptors: Immunhistochemical localization and role in mediating inhibition of adrenergic RVLM presympathetic neurons by catecholamines and clonidine. Ann. N. Y. Acad. Sci. 763:541-551; 1995.
201. Sun, M. K.; Regunathan, S.; Reis, D. J. Cardiovascular responses to agmatine, a clonidin-displacing substance, in anesthetized rats. Clin. Exp. Hypertens. 17:115-128; 1995.
202. Synetos, D.; Manolopoulos, V. G.; Atlas, D.; Pipili-Synetos, E. Human plama-derived material with clonidin-displacing substance (CDS)-like properties contracts the isolated rat aorta. J. Auton. Pharmacol. 11:343-351; 1991.
203. Szabo, B.; Urban, R.; Limberger, N.; Starke, K. Cardiovascular effects of agmatine, a "clonidine-displacing substance", in conscious rabbits. Naunyn Schmiedebergs Pharmacol. 351:268-273; 1995.
204. Szabo, B.; Urban, R.; Starke, K. Sympathoinhibition by rilmenidine in conscious rabbits-involvement of α-2 adrenoceptors. Naunyn Schmiedebergs Arch. Pharmacol. 348:593-600; 1993.
205. Takada, K.; Hayashi, T.; Mammoto, T.; Yamatodani, A.; Kitamura, S.; Yoshiga, I. The involvement of pertussis toxin-sensitive G proteins in the postreceptor mechanism of central I1-imidazoline receptors. Br. J. Pharmacol. 120(8):1575-1581; 1997.
206. Tesson, F.; Limon, I.; Parini, A. Tissue-specific localization of mitochondrial imidazoline-guanidium receptive sites. Eur. J. Pharmacol. 219:335-338; 1992.
207. Tesson, F.; Limon-Boulez, I.; Urban, P.; Puype, M.; Vandekerckhove, J. Localization of I2-imidazoline binding sites on monoamine oxidases. J. Biol. Chem. 270:9856-9861; 1995.
208. Tesson, F.; Prip-Buus, C.; Lemoin, A.; Pegorier, J. P.; Parini, A. Subcellular distribution of imidazoline-guanidinum-receptive sites in human and rabbit liver. J. Biol. Chem. 266:155-160; 1991.
209. Tibirica, E.; Feldman, J.; Bousquet, P. Contribution of catecholaminergic neurons of the dorsomedial and ventrolateral medulla oblongata to the hypotensive effect of clonidine in spontaneously hypertensive rats-in vivo voltametric studies. J. Hypertens. 10:1327-1334; 1992.
210. Tibirica, E.; Feldman, J.; Mermet, C.; Gonon, F.; Bousquet, P. An imidazoline specific mechanism for the hypotensive effect of clonidine: A study with yohimbine and idazoxan. J. Pharmacol. Exp. Ther. 256:606-613; 1991.
211. Tibirica, E.; Mermet, C.; Feldman J.; Gonon, F.; Bousquet, P. Correlation between the inhibitory effect on catecholaminergic ventrolateral medullary neurons and the hypotension evokedby clonidine: A voltametric approach. J. Pharmacol. Exp. Ther. 250:642-647; 1989.
212. Timmermans, P. B. M. W. M.; Schoop, A. M. C.; Kwa, H. Y.; Van Zwieten, P. A. Characterization of α-adrenergic receptors participating in central hypotensive and sedative effects of clonidine using yohimbine, rauwolscine and corynanthin. Eur. J. Pharmacol. 70:7-15; 1981.
213. Timmermans, P. B. M. W. M.; Van Zwieten, P. A. Alpha-adrenoceptors: Classification, localization, mechanisms and targets for drugs. J. Med. Chem. 25:1389-1401; 1982.
214. Tsoli, E.; Chan, S. L.; Morgan, N. G. The imidazoline I1 receptor agonistmoxonidine, inhibits insulin secretion from isolated rat islets of Langerhans. Eur. J. Pharmacol. 284:199-203; 1995.
215. Tsoucaris-Kupfer, D.; Bogaievsky, D.; Schmitt, H. Further investigations on the interaction between α-adrenoceptor agonists and central hypotensive effect of clonidine in rats, rabbits and dogs. Clin. Exp. Pharmacol. Physiol. 7:353-366; 1980.
216. Udvardy, E.; Schafer, S. G.; Végh, A.; Szekeres, L. Haemodynamic effects of a new centrally acting antihypertensive agent moxonidine as compared to clonidine. Eur. J. Pharmacol. 183:2064; 1990.
217. Urban, R.; Szabo, B.; Starke, K. Involvement of α-2 adrenoceptors in the cardiovascular effects of moxonidine. Eur. J. Pharmacol. 282:19-28; 1995.
218. Urban, R.; Szabo, B.; Starke, K. Is the sympathoinhibitory effect of rilmenidine mediated by α-2 adrenoceptors or imidazoline receptors? J. Pharmacol. Exp. Ther. 270:572-578; 1994.
219. Van Zwieten, P. A. Central imidazoline (I1) receptors as targets of centrally acting antihypertensives: Moxonidine and rilmenidine. J. Hypertens. 15:117-125; 1997.
220. Van Zwieten, P. A. Pharmacology of the α-2 adrenoceptor agonist rilmenidine. Am. J. Cardiol. 61:6D-14D; 1988.
221. Van Zwieten, P. A.; Thoolen, M. J. M. C.; Timmermans, P. B. M. W. M. The hypotensive activity and side-effects of methyldopa, clonidine and guanfacine. Hypertension 6(suppl. 11):28-33; 1984.
222. Vizi, E. S. A szív és érrendszer szabályozása. In: Vizi, E. S., ed. Human Farmakológia, A racionalis gyógyszerterápia alapjai. Budapest: Medicina Könyvkiadó Rt.; 1997:538-540.
223. Vizi, E. S. Presynaptic modulation of neurochemical transmission. Progr. Neurobiol. 12:181-289; 1979.
224. Vizi, E. S. Non-synaptic modulation of transmitter release: Pharmacological implications. TIPS 172-175; 1980.
225. Vizi, E. S. Non-synaptic interactions between neurons: Modulation of neurochemical transmission. Pharmacological and clinical aspects. Chichester/New York: John Wiley & Sons; 1984.
226. 2-adrenoceptors. J. Pharmacol. Exp. Ther. 238:701-706; 1986.
227. Vizi, E. S.; Kiss, J. P. Neurochemistry and pharmacology of the major hippocampal transmitter systems: Synaptic and non-synaptic interactions. Hippocampus 8:566-607; 1998.
228. Vizi, E. S.; Lábos, E. Nonsynaptic interactions at presynaptic level. Prog. Neurobiol. 37:145-163; 1991.
229. Vizi, E. S.; Kiss, J. P.; Elenkov, I. J. Presynaptic modulation of cholinergic and noradrenergic neurotransmisson: Interaction between them. News Physiol. Sci. 6:119-123; 1991.
230. Vollmer, R. R.; Buckley, J. P. Central cardiovascular effects of phentolamine in chloralose-anesthetized cats. Eur. J. Pharmacol. 43: 17-25; 1977.
231. Wang, H.; Otake, K.; Ruggerio, D. A.; Milner, T. A.; Li, G. Regional distribution of agmatine and arginine decarboxylase in rat brain. Soc. Neurosci. Abstr. 20:1060; 1994.
232. Wang, H.; Regunathan, S.; McGowan, D.; Bramwell, S.; Reis, D. J. An antiserum to idazoxan recognizes an immunreactive substance in human serum and cerebral spinal fluid which is not agmatine. Neurochem. Int. 30(1):85-94; 1997.
233. Wang, H.; Regunathan, S.; Meely, M. P.; Reis, D. J. Isolation and characterization of imidazoline receptor protein from bovine adrenal chromaffin cells. Mol. Pharmacol. 42:792-801; 1992.
234. Wang, H.; Regunathan, S.; Youngson, C.; Reid, D. J. An antibody to agmatine localizes the amine in bovine adrenal chromaffin cells. Neurosci. Lett. 183:1-5; 1995.
235. Wang, H.; Regunathan, S.; Ruggerio, D. A.; Reis, D. J. Production and characterization of antibodies specific for the imidazoline receptor protein. Mol. Pharmacol. 43:509-515; 1993.
236. Weber, M. A.; Graettinger, W. F.; Cheung, D. G. Centrally acting sympathetic inhibitors. In: Laragh, J. H.; Brenner, B. M., eds. Hypertension: Pathophysiology, diagnosis and management. New York: Raven Press; 1990:2251-2261.
237. Weitzel, G.; Pfeiffer, B.; Stock, W. Insulin-like partial effects of agmatine derivates in adipocytes. Hoppe Seylers. Z Physiol. Chem. 361:51-60; 1980.
238. Wikberg, J. E.; Uhlen, S. Further characterization of the guinea pig cerebral cortex idazoxan receptor: Solubilization, distinction from the imidazole site, and demonstration of cirazoline as an idazoxan receptor-selective drug. J. Neurochem. 55:192-203; 1990.
239. Wikberg, J. E. S. Dynamic properties of I2-receptors. Ann. N. Y. Acad. Sci. 763:43-56; 1995.
240. Yablonsky, F.; Dausse, J. P. Non-adrenergic binding sites for the "α 2-antagonist" (3H)idazoxan in the rabbit urethral smooth muscle. Pharmacological and biochemical characterisation. Biochem. Pharmacol. 41:701-707; 1991.
241. Yablonsky, F.; Riffaud, J. P.; Lacolle, J. Y.; Dausse, J. P. Evidence for non-adrenergic binding sites for (3H)idazoxan in the smooth muscle of rabbit urethra. Eur. J. Pharmacol. 154:209-212; 1988.
242. Youngson, C.; Regunathan, S.; Wang, H.; Li, G.; Reis, D. J. Coexpression of imidazoline receptors and agmatine in carotid body. Ann. N. Y. Acad. Sci. 763:440-444; 1995.
243. Zandberg, P.; De Yong, W.; De Wied, D. Effect of cathecholaminereceptor stimulating agents on blood pressure after application in the nucleus tractus solitarii of the medulla oblongata. Eur. J. Pharmacol. 55:43-56; 1979.
244. Zonnenschein, R.; Diamant, S.; Atlas, D. Imidazoline receptors in rat liver cells: A novel receptor subtype of α-2 adrenoceptors? Eur. J. Pharmacol. 190:203-215; 1990.